Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Consistency of Bivalent HPV Vaccine (Cecolin) Lots in Healthy Females
NCT04965350Phase 3Completed
- Sponsor
- Shanghai Zerun Biotechnology Co., Ltd.
- Start
- Apr 2021
- Primary completion
- Apr 2022
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of recombinant human papillomavirus bivalent (types 16, 18) vaccine in human papillomavirus infection (4 arms), sponsored by Shanghai Zerun Biotechnology Co., Ltd. Primary endpoints: Geometric Mean Titers for HPV-16 and/or HPV-18 at Month 7 and Percentage of participants who seroconvert to HPV-16 and/or HPV-18 at Month 7. Started Apr 2021; status: completed.
02
Drugs
recombinant human papillomavirus bivalent (types 16, 18) vaccine
03
Conditions
human papillomavirus infection
Beyond the preview
Go deeper on NCT04965350.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04965350.